Organon (OGN) stock

Medicines , market cap $3.6B

Medicines

Market cap $3.6B

$13.82

-0.14%

As of Monday's close · Live for Pro members at the open

Quality Score

Below Average

In its industry

#52of 92

Pharma

Checks firing

8of 14

Trending up

From 52-week high

-0.2%

Above the 200-day

OGN's Quality Score was unchanged on Mon, Nov 2, at 0.

Follow OGN's trial news. Pro members can get an alert when Organon files news, and see its trials, share raises, and its CEO's filings.

Get an alert when OGN files news on its trialSee it live, free until Wednesday morning. No account. No card. Then keep going with a free account.

We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.

Why is OGN up?

Up 112% in a year while the S&P 500 rose 12%.

Investors now pay $19 for each $1 of yearly profit, up from $2 on Oct 30, 2025.

Sources: Price history, Oct 30, 2026; Annual reports, Dec 31, 2025

1 more reason, free with an account →1 more reason why OGN beats the market, from its filings, with the timeline, for Pro members.

Key facts on OGN

Key facts on OGN
Latest filing	10-Q, Jul 31 Filed its quarterly report (10-Q) for the quarter to Jun 30, 2026

What's next

Mon Nov 9: Ex-dividend, $0.02 a shareAt the open. Pays Dec 10.

OGN catalysts

Coming up

After its last 4 reports it closed -2.2% on average, higher 1 of 4 times.

19 past catalysts since 2021, with sizes and sources, for Pro members.Get in free →

What's next for OGN

Dilution on the horizon

No shelf registration or at-the-market program on file in the last three years.

For Pro members: the amounts, and the share count against a year ago.

Insiders

Head of Mfg & Supply Juliana Papa Drinane sold 14,761 shares on Aug 5. 2 more insider trades this year.

From Form 4: open-market buys and sales only.

Get an alert when Joseph Morrissey Jr. buys or sells

For Pro members: every trade, and Joseph Morrissey Jr.’s 6 filings and quotes.

Get an alert when OGN files news on its trialSee it live, free until Wednesday morning. No account. No card. Then keep going with a free account.

See every upcoming FDA date →

FDA dates in the next 60 days

Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.

DateStockDrug

In 20 daysFDA decisionIn 20 days · FDA decisionCAPRCapricor TherapeuticsDeramiocelCAPRCapricor Therapeutics · $385MDeramiocelFDA decision due (PDUFA)
In 20 daysFDA decisionIn 20 days · FDA decisionSVRASavaraMolgramostimSVRASavara · $1.0BMolgramostimFDA decision due (PDUFA)
In 50 daysFDA decisionIn 50 days · FDA decisionMLYSMineralys TherapeuticsLorundrostatMLYSMineralys Therapeutics · $1.9BLorundrostatFDA decision due (PDUFA)

11 more FDA dates and 102 trial data dates in the next 60 days, each on the FDA calendar. Pro members see whether each company's cash lasts past its date, with an optional alert before it. See all 143 dates, ranked →

Why OGN scores 0

Below Averagefor quality, not price, 8 of 14 chart checks firingWhat the Quality Score means

+8Chart checks 8 of 14 firing right now, one point each
+2Long-term trend above a rising 200-⁠day average, near its 52-⁠week high, down over two years

Run-up adds
Profit addsRead on the last four quarters against the four before, or the last full year where no quarters are filed.
Growth subtractsSales and margins against a year earlier: up to +3 for fast growth and widening margins, down to -2 when both shrink.

No effect today: Size, Dilution, Volatility, Cash flow, Persistence, News, and Insider trades.

What every line is worth, and the reason behind it, on OGN and every other stock.Get in free →

Price, score, chart checks, and the industry rank are from a snapshot taken at 9:36 PM ET, at least 15 minutes behind. How we rank stocks.

Tested. Our top-⁠scored stocks returned 2.2x the average stock over the next month. How we tested it

Alert me when OGN's Quality Score turns up

See it live, free until Wednesday morning. No account. No card. Then keep going with a free account.

Here is what Pro members see.

The same page for Pro members, on AMD
Its Quality Score and rank, the line that drives it, and the live price.
The full chart
A year of candles to start, out to the whole history, with insider trades marked and the Quality Score under the price.
Every line of the score
Price action, the company, and signals, each with its points, on OGN and every other stock.
FDA dates, counted down
Each date in the company's words, its cash against the date, and an optional alert before it.
CEOs buying their own stock
Every CEO buy, biggest names first. Sort, filter, save the list, and set optional alerts.
Congress trades
A member's trades, newest first, each with its amount. Sort and filter the whole list.
14 chart checks, read for you
The ones firing on the stock, each in plain words, its rule a tap away.
Earnings, week by week
Who reports each day, and how each stock took its last four reports.
The market map
Every stock a box, colored by its Quality Score.
Themes, ranked live
Each theme's stocks ranked by Quality Score, live. Here, AI chips.
The top 10, every day
The ten highest Quality Scores at each close, kept day by day, week by week.
Optional alerts, your way
Pick a stock, a score, a price, a filing, or a whole scan. It tells you by push or email.
Your watchlist, scored
Your stocks by Quality Score, today's move, or name.
On your phone and your laptop
The same account and watchlist on both, each laid out for its screen.

Prices refresh every 2.5 seconds during market hours.
Optional alerts by push, email, or the bell.
Add it to your Home Screen and it opens like an app.

OGN has 8 of 14 chart checks firing

Trend1 of 5 shown

MA FAN 21 EMA W.EMA HH/HL 52W HI

Volume1 of 3 shown

VOL VDU U/D VOL

Tight range1 of 3 shown

ATR SQZ SQUEEZE NR7

Buying1 of 3 shown

OBV+CLOSE HI SPRING

The other 10 checks on OGN, and all 14 on every stock.Get in free →

OGN RSI today: 62.6, above its 50-day and 200-day averages

Not scored

Not in the Quality Score: over 20 years of tests, 2006 to 2026, they added no edge.

RSI 1462.6
Above 50, below 70.
MACD (12, 26, 9)Above signal
Crossed above its signal line 2 sessions ago.
50-day average$13.74
The price is 0.6% above it.
200-day average$11.54
The price is 19.8% above it.
50/200 crossGolden cross
The 50-day crossed above the 200-day on May 12.
ADX 1429.8
25 or more, with +DI above -DI.
Support$13.71
Swing low from Oct 19, 0.8% below the price.
Resistance$13.83
Swing high from Oct 9, 0.1% above the price.
52-week high$13.85
From Nov 2, 0.2% above the price.
52-week low$5.69
From Mar 30, 58.8% below the price.
Chart patternNone
No triangle, channel, or wedge in the last year.
Bollinger Bands (20, 2)Inside
The bands run from $13.71 to $13.83.
Volume0.9x
Against its 20-day average, for the time of day.

The deep dive on OGN

What it does and how it makes money6 findings"On February 24, 2025, Organon received a Paragraph IV Certification Letter notifying the Company that Xiromed Pharma Espana …" (10-K for fiscal 2025)SEC filing · Feb 24, 2026
Where it stands4 findingsFor Pro members4 findings on where OGN stands: its cash, debt, and share count, for Pro members
What changed in its filings2 findings"On April 2, 2025, the Company sued Xiromed in the U.S. District Court for the District of New Jersey asserting that the filing of the ANDA infringed the ‘037 patent and ‘552 patent and triggering a stay of regulatory approval of Xiromed’s ANDA for up to 30 months." (10-Q for the quarter to Jun 30, 2026)SEC filing · Jul 31, 2026
Who holds and trades it4 findingsFor Pro members4 findings on who holds and trades OGN, for Pro members
Against its closest peers1 peerNet income over four quarters: OGN $209M, PRGO -$1.73B.

14 more findings on OGN, each with its source, for Pro membersGet in free →

How OGN ranks in Pharma

OGN is #52 of 92 by Quality Score.

How OGN ranks in Pharma
1	ABBVAbbVie	6/14	21
2	LLYEli Lilly	6/14	20
3	GMABGenmab	5/14	18
	NVSNovartis		Open for its score
	OCSOculis		Open for its score
	OMEROmeros		Open for its score
	OPKOpko Health		Open for its score
52	OGNOrganon	8/14	0

Net income over four quarters: OGN $209M, PRGO -$1.73B.

When does OGN report earnings, and what happens after?

Expected to report Thu Feb 11, before the open (in 101 days). Expected.

What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.

-0.7%0.0%+0.2%

Apr 30Jul 31Oct 30

Reported	When	Gap	Reaction	5 sessions
Oct 30, 2026Before open	Before open	+0.1%	+0.2%	open
Jul 31, 2026Before open	Before open	0.0%	0.0%	0.0%
Apr 30, 2026Before open	Before open	-0.1%	-0.7%	+0.5%

OGN closed higher after 1 of its last 4 reports.

All 4 reports, and OGN's Quality Score going into each

OGN sales and profit by year

Sales and profit by year

Sales grew in two of the last six years, to $6.2B in 2025. It made a profit in each of the seven years.

Insiders trading OGN

OGN insider trades

One insider sold $200K across 1 filing in the last 6 months. No open-⁠market buys on record. The newest:

SellJuliana Papa Drinane$200KHead of Mfg & Supplyat $13.57 on Aug 5, filed Aug 5

SellJuliana Papa DrinaneHead of Mfg & Supply$200Kat $13.57 on Aug 5, filed Aug 5

OGN trades by Congress and the executive branch

3 trades disclosed in the last six months. The newest:

SellDonald Trump$15K to $50KPresident (R)traded Jul 29, disclosed Sep 22(55 days later)

SellDonald TrumpPresident (R)$15K to $50Ktraded Jul 29, disclosed Sep 22(55 days later)

All 3 trades on OGN disclosed by Congress and the executive branch, for Pro members.Get in free →

See what Congress is buying across the market

OGN's officers and directors

Officers and directors with a Form 4 in the last 12 months.

Joseph T. Morrissey Jr.Interim CEO
Carrie Smith CoxExecutive Chair · 1 trade
Matthew M. WalshChief Financial Officer
Juliana Papa DrinaneHead of Mfg & Supply · 1 trade
Lynette HolzbaurSVP and Corporate Controller · 1 trade
Aaron FalcioneChief Human Resources Officer
Daniel KarpExecutive VP, Corp. Dev.
Ferreira Juan Camilo ArjonaHead of R&D & CMO

3 more officers and directors file at OGN. Each page above names the rest.

See insider trades by person

Which ETFs hold OGN?

In ETFs: OGN is under 0.1% of VYM and under 0.1% of VTI, the most of the 24 funds Breakaway covers, by each fund's latest filing, Jun 30 to Jul 31, 2026.

About Organon

Organon & Cois a globalised healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. Its operations include the following product portfolios: Women's Health: Itbwomen's health portfolio of products is sold by prescription mainly in two therapeutic areas: contraception, with key brands such as Nexplanon, and fertility, with key brands such as Follistim. other women's health products include the Jada, which is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. The General Medicines portfolio includes biosimilars and established brands. Companies' current biosimilars portfolio spans across immunology and oncology-related treatments.

10,000 employeesJersey City, NJorganon.com

What Organon says it competes with

“We conduct our business in highly competitive markets which mirror the equally competitive pharmaceutical industry.”

From its annual report, SEC filing · Feb 24, 2026

2 more sentences, what it says it does, and its sales by region, for Pro membersGet in free →

OGN's score card

Organon (OGN): Quality Score 0, Below Average, #52 of 92 in Pharma, with its price, on Breakaway — The picture a link to this page shows when it is shared.

Pro members see every line of every stock's score.

2 more filings explained, a plain line each
Real-⁠time prices, no delay
Every line of OGN's score, with the points and the reason

BreakawaySep 22Donald Trump sold OGN$15K to $50K, disclosed Sep 22

Alerts are optional.

See OGN's 14 chart checks

See it live, free until Wednesday morning. No account. No card. Then keep going with a free account.

Straight Answers

As of Nov 2, 2026: OGN's Quality Score is 0 (Below Average), #52 of 92 in Pharma. Insiders sold $200K in the last 6 months (Form 4).

Is OGN a good stock to buy? What its Quality Score says

OGN scores 0 today, which Breakaway calls Below Average. It is #52 of 92 in Pharma by Quality Score, with 8 of 14 chart checks firing. Up 112% in a year while the S&P 500 rose 12%. Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.

What is OGN's Quality Score?

OGN scores 0 today, which Breakaway calls Below Average (0 to 5). That is #52 of 92 in Pharma by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind OGN's 0.

Are insiders buying OGN?

One insider sold $200K across 1 filing in the last 6 months. No open-⁠market buys on record. The newest is Juliana Papa Drinane, Head of Mfg & Supply, who sold $200K on Aug 5.

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.